High-dose methotrexate in pediatric oncology-back to bench from bedside for a while?

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 2, 2009, Pages 151-152

  Sterba, Jaroslav ^a   Valík, Dalibor ^b   Bajciova, Viera ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; METHOTREXATE; ANTIDOTE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; CANCER MORTALITY; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LETTER; LOW DRUG DOSE; MEDICAL LITERATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; CHILD; DOSE RESPONSE; NOTE;

ANTIDOTES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUCOVORIN; METHOTREXATE;

EID: 60849095824     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181914733     Document Type: Letter

References (13)

1. Kamen BA. High-dose methotrexate: insecure rationale Take 2. Pediatr Hematol Oncol. 2008;30:639-640.
2. Maria Teresa Amparo Buendia H, Juan L, Gloria Elena Suarez V, et al. The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia. Pediatr Hematol Oncol. 2008;30:643-650.
3. Borsi JD, Wesenberg F, Stokland T, et al. How much is too much? Folinic acid rescue dose in children with acute lympho-blastic leukaemia. Eur J Cancer. 1991;27: 1006-1009.
4. Hills R, Ive FA. Folinic acid rescue used routinely in psoriatic patients with known methotrexate "sensitivity." Acta Derm Venerol. 1992;72:438-440.
5. Browman GP, Goodyear MD, Levine MN, et al. Modulation of the antitumor effect of methotrexate by low-dose leucovorine in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol. 1990;8: 203-208.
6. Takacs P, Rodriguez L. High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet. 2005;89:301-302.
7. Valik D, Radina M, Sterba J. Homocysteine: exploring its potentials: a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics. 2004;5: 1151-1162.
8. Valik D, Sterba J, Bajciova V, et al. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology. 2005;69:269-272.
9. Sterba J, Valik D, Bajciova V, et al. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma. 2005;52:456-463.
10. Sterba J, Dusek L, Demlova R, et al. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited. Clin Chem. 2006;52:692-700.
11. Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lympho-blastic leukemia. Leukemia. 2006;20: 1955-1962.
12. http://www.cancer.gov/search/ViewClinical-Trials.aspx?cdrid= 349182&version=patien &protocolsearchid=5111870#AlternateTitle- CDR0000349182.
13. von Stackelberg A, Hartmann R, Buhrer C, et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood. 2008;111:2573-2580.